Deep Intelligent Pharma (DIP), a leading AI-driven drug research and development platform based in Singapore, has successfully completed a Series D financing round, raising almost $50 million. This funding was spearheaded by CDH Baifu, with ongoing support from existing investors Xinding Capital and HongShan Capital. Index Capital acted as the exclusive financial advisor for this funding round.
The capital acquired will be utilized primarily to enhance DIP”s end-to-end autonomous clinical system and to broaden its global commercialization efforts. This initiative is set to facilitate a significant transformation from basic “assistive tools” to robust “decision-making infrastructure” within the biotech industry.
The biotech sector in Asia, particularly in China, is experiencing a transformative phase often referred to as a “DeepSeek moment.” This term denotes the rapid development of drugs at unprecedented rates and scales. DIP”s AI technology is a key driver of this progress, significantly reducing clinical trial expenses, shortening development timelines, and boosting success rates.
In traditional drug research and development, companies face a “dual dilemma” characterized by protracted development cycles and exorbitant costs. Approximately 40% of clinical trial failures are linked to flaws in design or execution. As a result, there is a pressing need for advanced “intelligent decision systems” that can effectively mitigate risks, moving beyond the conventional model of outsourcing manpower.
According to Li Xing, the Founder and CEO of DIP, the company”s success is redefined not merely by completing tasks but by achieving meaningful outcomes. “Through AI intervention, we simulate a full-dimension “commercial endpoint” analysis in early clinical stages,” he stated, emphasizing the goal of maximizing drug asset success rates.
After extensive research, DIP has developed an innovative “human-brain-like multi-agent ecosystem” known as the Synaptic Agent Ecosystem, which boasts three core advantages: Cognitive Atomism, Human-brain Bionics, and Extreme Precision. These features enable the decomposition of intricate clinical logic into over 10,000 high-precision “atomic Agents,” each functioning with the expertise of a specialist while collaborating effectively.
DIP”s approach has led to notable real-world applications, such as its work with Immunorock, a Japanese company focused on oral cancer vaccines. DIP”s AI-driven protocol design for Immunorock enabled a swift completion and submission of a critical clinical trial protocol, identifying potential flaws that could lead to increased patient dropout rates. This proactive strategy allowed Immunorock to pass regulatory reviews efficiently, saving substantial time and ensuring compliance.
Industry experts recognize DIP”s methodology as a groundbreaking shift in the pharmaceutical research and development landscape. Cao Xu from CDH Baifu remarked that DIP is not just delivering a technical tool but is fundamentally changing the logic of pharmaceutical R&D. Zhang Chi from Xinding Capital added that DIP has transitioned from providing point-based technology to establishing a comprehensive system-level platform, creating a formidable competitive advantage.
Founded in 2017, Deep Intelligent Pharma is committed to revolutionizing the entire drug development lifecycle through the power of artificial intelligence. By uniting top AI scientists and experienced clinical professionals globally, DIP aims to offer pharmaceutical companies intelligent solutions that enhance the precision, efficiency, and economy of drug research and development.
